Related references
Note: Only part of the references are listed.Short-term effectiveness and safety of tofacitinib in ulcerative colitis-real world data from tertiary medical centers in Israel
Irit Avni-Biron et al.
DIGESTIVE AND LIVER DISEASE (2022)
Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis
Carlos Taxonera et al.
INFLAMMATORY BOWEL DISEASES (2022)
Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
Natsuki Ishida et al.
DIGESTIVE DISEASES AND SCIENCES (2022)
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na et al.
INTESTINAL RESEARCH (2022)
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Parakkal Deepak et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
Maria Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2021)
Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment
Sun-Ho Lee et al.
INFLAMMATORY BOWEL DISEASES (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Sa082 EFFICACY AND SAFETY OF TOFACITINIB TREATMENT FOR 1 YEAR IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS IN A SPECIALIZED IBD CENTER
Kentaro Kojima et al.
GASTROENTEROLOGY (2021)
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort study
K. Oh et al.
JOURNAL OF CROHNS & COLITIS (2021)
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
Hiromichi Shimizu et al.
INTESTINAL RESEARCH (2021)
Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study
Eun Hye Oh et al.
GUT AND LIVER (2020)
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
Loriane Lair-Mehiri et al.
DIGESTIVE AND LIVER DISEASE (2020)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea
Jae Myung Cha et al.
GUT (2020)
P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre
K Watanabe et al.
Journal of Crohns & Colitis (2020)
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
A Cremer et al.
Journal of Crohns & Colitis (2020)
P662 Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
N Yoshimura et al.
Journal of Crohns & Colitis (2020)
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience
Sailish Honap et al.
JOURNAL OF CROHNS & COLITIS (2020)
The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis
Rebecca K Grant et al.
INFLAMMATORY BOWEL DISEASES (2020)
Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
Peter Hoffmann et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Real-World Experience with Tofacitinib in IBD at a Tertiary Center
Roni Weisshof et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
Stephen Hanauer et al.
JOURNAL OF CROHNS & COLITIS (2019)
Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis
Tingbin Xie et al.
GASTROENTEROLOGY REPORT (2018)
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
Satoshi Motoya et al.
INTESTINAL RESEARCH (2018)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea
Hyungil Seo et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)
Albumin as a prognostic marker for ulcerative colitis
Nabeel Khan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi et al.
INTESTINAL RESEARCH (2017)
The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score
Kentaro Ikeya et al.
JOURNAL OF CROHNS & COLITIS (2016)
Prediction of clinical and endoscopic responses to anti-tumor necrosis factor- antibodies in ulcerative colitis
Yukihiro Morita et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study
Ryota Iwasa et al.
BMC GASTROENTEROLOGY (2015)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Correlation of C-Reactive Protein with Clinical and Endoscopic Activity in Patients with Ulcerative Colitis
Sami Karoui et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
ANNALS OF INTERNAL MEDICINE (2007)
CRP correlates with clinical score in ulcerative colitis but not in Crohn disease's
Alexander D. Rodgers et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
